INFLUENCE OF METABOLIC THERAPY ON LIFE QUALITY IN PATIENTS WITH ATRIAL FIBRILLATION PAROXYSMS

Abstract

Abstract. The goal of the study was to investigate the effect of magnesium orotate as a part of complex therapy in sinus rhythm restoring in patients with AF paroxysm, as well as to evaluate its effectiveness and effect on LQo with long-term use. Materials and research methods. We examined 56 patients (16 women and 40 men) with an average age of (61,5 ± 4,3) years with paroxysmal atrial fibrillation. All patients were divided into two groups. Patients of the 1st group (n=28) underwent medical cardioversion with amiodarone and magnesium orotate. Patients of the 2nd group (n=28) received only amiodarone. The time of sinus rhythm restoration, parameters of electrical instability of the atrial and ventricular myocardium after sinus rhythm restoration, patients life quality 3 months after discharge - were assessed in both groups. Results. The study allowed to reveal that the addition of magnesium orotate to the basic therapy of patients with atrial fibrillation increases the effectiveness of medical cardioversion and reduces the time of its onset. When using amiodarone and magnesium orotate, signs of electrical instability of the atrial myocardium (the number of paired and supraventricular extrasystoles) are significantly less according to the results of Holter electrocardiogram monitoring compared with amiodarone monotherapy. Atrial fibrillation caused a life quality parameters deviations in the form of an increase in the severity of the disease symptoms, physical activity limitation and psycho-emotional sphere disorders. 3 months after the treatment, it was noted that life quality in patients of the 1st group (complex therapy using magnesium orotate) was higher compared to patients of the 2nd group due to the improvement in the indicators of the "psycho-emotional" component. Conclusions. The addition of magnesium orotate to the basic therapy of paroxysmal atrial fibrillation can significantly improve the clinical course of the disease in patients and their life quality after 3 months treatment period.